NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
7 trialsNCT04886531 2026-03-12
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04965064 2025-12-15
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
University of Rochester
Phase 2 Recruiting
NCT06008275 2025-11-10
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Baylor Research Institute
Phase EARLY_PHASE1 Recruiting
NCT05760612 2025-09-25
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT05388149 2025-01-31
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
University Health Network, Toronto
Phase 2 Recruiting
NCT06693024 2024-11-20
NeraHER2
Peking University People's Hospital
Recruiting